Cannabis Bioscience International Holdings, Inc. (CBIH)
- GlobeNewswire
Unleashing the Potential of Cannabis: Cannabis Bioscience International Holdings Reaches a Historic Valuation
HOUSTON, June 17, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH), a company dedicated to medicinal cannabis research for over 15 years, has achieved a 2 billion dollar valuation. This achievement is a testament of the paradigm shift which will allow patients and the medical industry to consider cannabinoids as the first option, not a last resource. Our significant valuation is the outcome of our unwavering dedication to growth and our persistent commit
- GlobeNewswire
CBIH and Vita Biotech Forge Alliance to Propel Clinical Studies Forward
HOUSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Vita Biotech Research has entered into a significant partnership with Cannabis Bioscience International Holdings (OTCMKTS: CBIH), to fund the clinical data collection efforts of CBIH’s rigorous data clinical studies, underscoring Vita Biotech's commitment to supporting cutting-edge research and ensuring the highest standards of clinical data integrity. Through this strategic alliance, Vita Biotech will act as a financial subsidiary and catalyst for CBIH
- GlobeNewswire
Cannabis Bioscience International Holdings Announces Effectiveness of Form S-1 Registration Statement
HOUSTON, TX , Dec. 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH) announces that its registration statement on Form S-1 (File No. 333-267039) (the “Registration Statement”), filed under the Securities Act of 1933 (the “Securities Act”), was declared effective by the United States Securities and Exchange Commission (the “SEC”) on December 5, 2023. This declaration does not imply that the SEC has approved or disapproved the offer o
